NFL Biosciences (XPAR:ALNFL) Cash-to-Debt : 40.79 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NFL Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NFL Biosciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 40.79.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, NFL Biosciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for NFL Biosciences's Cash-to-Debt or its related term are showing as below:

XPAR:ALNFL' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.4 Med: 26.17 Max: No Debt
Current: 40.79

During the past 6 years, NFL Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 1.40. And the median was 26.17.

XPAR:ALNFL's Cash-to-Debt is ranked better than
70.58% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs XPAR:ALNFL: 40.79

NFL Biosciences Cash-to-Debt Historical Data

The historical data trend for NFL Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NFL Biosciences Cash-to-Debt Chart

NFL Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

3.65

37.71

14.63

40.79

NFL Biosciences Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			37.71	25.12	14.63	24.38	40.79

Competitive Comparison of NFL Biosciences's Cash-to-Debt

For the Biotechnology subindustry, NFL Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NFL Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NFL Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NFL Biosciences's Cash-to-Debt falls into.

NFL Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NFL Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.529	/	(0.062	+	0)
	=	40.79

NFL Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.529	/	(0.062	+	0)
	=	40.79

NFL Biosciences (XPAR:ALNFL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

NFL Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NFL Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NFL Biosciences (XPAR:ALNFL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (XPAR:ALNFL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

82F:Germany

Address

199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170

Website

https://www.nflbiosciences.com/

NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

NFL Biosciences (XPAR:ALNFL) Headlines

No Headlines